The Reply - 20/06/16
Doi : 10.1016/j.amjmed.2016.01.046
Brittany L. Melton, PhD, PharmD a, Alissa L. Russ, PhD b, c, d, e, Alan J. Zillich, PharmD b, c, d, e, M. Sue McManus, PhD, NP f, Michael Weiner, MD, MPH b, c, d
a School of Pharmacy, University of Kansas Medical Center, Kansas City
b Center for Health Information and Communication, Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, Indianapolis, Ind
c Regenstrief Institute, Inc, Indianapolis, Ind
d Indiana University Center for Health Services and Outcomes Research, Indianapolis
e College of Pharmacy, Purdue University, West Lafayette, Ind
f Department of Veterans Affairs, Nephrology Services Central Texas, Temple
Le texte complet de cet article est disponible en PDF.
| Funding: This work was supported by Veterans Affairs Health Services Research & Development (VA HSR&D) grant #PPO 09-298 (Principal Investigator: ALR). ALR and AJZ were supported by VA HSR&D Research Career Development Awards (CDA 11-214, and RCD 06-304-1, respectively). The views expressed in this response are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US government. |
|
| Conflict of Interest: None for all authors. |
|
| Authorship: All authors contributed to the content of this letter. |
© 2016
Elsevier Inc. Tous droits réservés.
Vol 129 - N° 7
P. e97 - juillet 2016 Retour au numéro
Article précédent
- Allopurinol Dose Reductions Based on Creatinine Alert Redesign System
- Angelo L. Gaffo, Ted R. Mikuls, Lisa K. Stamp, Tuhina Neogi
- South Sudan to Martha's Vineyard: Malaria Always First!
- Spinello Antinori, Laura Milazzo, Salvatore Sollima, Mario Corbellino
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?